Pycnogenol reduces CRP and improves OA

22 December 2008

Pycnogenol, an antioxidant plant extract from the bark of the French maritime pine tree, has been shown to alleviate the symptoms of osteoarthritis in a study published in the December issue of the journal Redox Report. In the 55-patient analysis, as well as improving OA and pain, the agent significantly lowered plasma levels of the inflammatory marker C-reactive protein.

Results showed that Pycnogenol, which is owned by Guernsey firm Horphag Research, significantly lowered CRP from average 3.9mg/L at baseline to 1.1mg/L, reflecting essentially healthy levels. In the placebo group, a marginally lower CRP level was detected. Other blood parameters indicative of acute inflammation likewise decreased with Pycnogenol, such as fibrinogen (lowered 37.1 %) and reactive oxygen species (down 29.9 %).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight